Status
Conditions
Treatments
About
Male and female subjects age 18-85 with lung disease will inhale 5ml/kg (patient body weight) hyperpolarized helium and will be scanned using MRI at 3 Tesla, to evaluate the Apparent Diffusion Coefficient (ADC), ventilation defect volume and percent ventilation.
Full description
Briefly, during a one to two hour visit, subjects will provide written informed consent and then undergo:
Full pulmonary function tests including spirometry, plethysmography and diffusing capacity of carbon monoxide (DLCO), Lung Clearance Index (LCI) and Airwave Oscillometry (AO) will be performed according to ATS guidelines. MedGraphics Elite Series, MedGraphics Corporation. St. Paul, MN USA and/or nDD EasyOne Spirometer, nDD Medical Technologies Inc. Andover, MA USA will be used. All measurements will be performed in the Pulmonary Function Laboratory at Robarts Research Institute.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
66 participants in 1 patient group
Loading...
Central trial contact
Grace Parraga, PhD; Angela A Wilson, RRT
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal